Aprogen Medicines Inc. (KRX:007460)
South Korea · Delayed Price · Currency is KRW 293.00
-24.00 (-7.57%)
Apr 15, 2026, 9:54 AM KST
Aprogen Medicines Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 117,974 | 150,114 | 150,578 | 78,349 | 26,296 |
Other Revenue | -0 | - | -0 | -0 | 0 |
| 117,974 | 150,114 | 150,578 | 78,349 | 26,296 | |
Revenue Growth (YoY) | -21.41% | -0.31% | 92.19% | 197.95% | -79.32% |
Cost of Revenue | 86,803 | 115,818 | 116,380 | 78,143 | 31,513 |
Gross Profit | 31,171 | 34,295 | 34,198 | 205.9 | -5,217 |
Selling, General & Admin | 62,781 | 52,138 | 66,149 | 67,621 | 43,833 |
Research & Development | 51,704 | 56,835 | 42,817 | 38,561 | 32,780 |
Amortization of Goodwill & Intangibles | 886.63 | 981.74 | 1,291 | 1,181 | 542.9 |
Other Operating Expenses | 991.68 | 793.02 | 872.25 | 733.32 | 760.94 |
Operating Expenses | 126,741 | 121,102 | 129,168 | 117,150 | 90,590 |
Operating Income | -95,571 | -86,807 | -94,970 | -116,944 | -95,807 |
Interest Expense | -4,764 | -1,007 | -631.84 | -9,906 | -21,764 |
Interest & Investment Income | 7,034 | 4,861 | 3,683 | 3,031 | 2,206 |
Earnings From Equity Investments | -39,375 | -0.09 | - | -1,210 | -1,734 |
Currency Exchange Gain (Loss) | 153.68 | 761.97 | 30.76 | -113.93 | -44.53 |
Other Non Operating Income (Expenses) | 35,328 | -11,780 | -428.55 | 22,216 | -379.06 |
EBT Excluding Unusual Items | -97,195 | -93,971 | -92,316 | -102,926 | -117,523 |
Gain (Loss) on Sale of Investments | 1,749 | 303 | 341.93 | -3,244 | -9,036 |
Gain (Loss) on Sale of Assets | -55,574 | -3,716 | 30.3 | -235.89 | -287.07 |
Asset Writedown | -739.83 | -801.87 | -2,271 | -9,162 | -223.61 |
Other Unusual Items | 9,449 | -503.07 | -1,024 | -42.95 | 7,728 |
Pretax Income | -142,310 | -98,689 | -95,239 | -115,611 | -119,341 |
Income Tax Expense | -1,739 | 1,687 | 2,044 | 473.8 | -111.74 |
Earnings From Continuing Operations | -140,571 | -100,376 | -97,283 | -116,085 | -119,229 |
Net Income to Company | -140,571 | -100,376 | -97,283 | -116,085 | -119,229 |
Minority Interest in Earnings | 70,368 | 42,296 | 41,664 | 17,428 | 25,309 |
Net Income | -70,202 | -58,079 | -55,619 | -98,657 | -93,920 |
Net Income to Common | -70,202 | -58,079 | -55,619 | -98,657 | -93,920 |
Shares Outstanding (Basic) | 20 | 17 | 16 | 13 | 12 |
Shares Outstanding (Diluted) | 20 | 17 | 16 | 13 | 12 |
Shares Change (YoY) | 15.24% | 9.30% | 16.69% | 16.73% | 206.64% |
EPS (Basic) | -3540.00 | -3375.00 | -3532.57 | -7355.49 | -8125.79 |
EPS (Diluted) | -3540.00 | -3375.00 | -3540.00 | -7461.18 | -8125.79 |
Free Cash Flow | -41,651 | -57,662 | -83,669 | -133,101 | -119,132 |
Free Cash Flow Per Share | -2100.28 | -3350.77 | -5314.11 | -9864.93 | -10307.07 |
Gross Margin | 26.42% | 22.85% | 22.71% | 0.26% | -19.84% |
Operating Margin | -81.01% | -57.83% | -63.07% | -149.26% | -364.35% |
Profit Margin | -59.51% | -38.69% | -36.94% | -125.92% | -357.17% |
Free Cash Flow Margin | -35.30% | -38.41% | -55.57% | -169.88% | -453.05% |
EBITDA | -71,974 | -62,501 | -65,899 | -88,552 | -70,545 |
EBITDA Margin | -61.01% | -41.64% | -43.76% | -113.02% | -268.27% |
D&A For EBITDA | 23,597 | 24,305 | 29,071 | 28,392 | 25,262 |
EBIT | -95,571 | -86,807 | -94,970 | -116,944 | -95,807 |
EBIT Margin | -81.01% | -57.83% | -63.07% | -149.26% | - |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.